Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus.

Autor: Perez-Guerrero, Edsaul Emilio, Gamez-Nava, Jorge Ivan, Muñoz-Valle, Jose Francisco, Cardona-Muñoz, Ernesto German, Bonilla-Lara, David, Fajardo-Robledo, Nicte Selene, Nava-Zavala, Arnulfo Hernan, Garcia-Cobian, Teresa Arcelia, Rincón-Sánchez, Ana Rosa, Murillo-Vazquez, Jessica Daniela, Cardona-Müller, David, Vazquez-Villegas, Maria Luisa, Totsuka-Sutto, Sylvia Elena, Gonzalez-Lopez, Laura
Předmět:
Zdroj: Clinical & Experimental Medicine; Feb2018, Vol. 18 Issue 1, p109-117, 9p
Abstrakt: Around 25% of patients with systemic lupus erythematosus (SLE) could be refractory to conventional therapies. P-glycoprotein expression on cell surface has been implied on drug resistance, however, to date, it is unknown if P-gp serum levels are associated with SLE disease activity. Evaluate the association of serum P-gp levels and SLE with disease activity despite treatment. A cross-sectional study was conducted on 93 female SLE patients, all receiving glucocorticoids at stable doses for the previous 6 months before to baseline. SLE patients were classified into two groups: (a) patients with active disease [SLE disease activity index (SLEDAI) ≥ 3] despite treatment, and (b) patients with inactive disease (SLEDAI < 3) after treatment. Forty-three healthy females comprised the control group. Serum P-gp, anti-DNA, and both anti-nucleosome antibody levels were measured using ELISA. Active-SLE patients despite treatment had higher P-gp levels compared with inactive-SLE after treatment (78.02 ng/mL ± 114.11 vs. 33.75 ng/mL ± 41.11; p = 0.018) or versus reference group subjects (30.56 ng/mL ± 28.92; p = 0.011). P-gp levels correlated with the scores of SLEDAI (r = 0.26; p = 0.01), Mexican-SLEDAI (MEX-SLEDAI) (r = 0.32; p = 0.002), SLICC/ACR damage index (r = 0.47; p < 0.001), and with prednisone doses (r = 0.33; p = 0.001). In the multivariate model, the high P-gp levels were associated with SLICC/ACR score (p = 0.001), and SLEDAI score (p = 0.014). Our findings support a relationship between serum P-gp levels and SLE with disease activity despite treatment, but it requires further validation in longitudinal studies. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: